Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT00887822
A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT00887341
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT00885755
- Locations
- π¬π§
Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom
π¦πΊMount Medical Center, Perth, Western Australia, Australia
πΈπͺKarolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 389
- Registration Number
- NCT00884507
Influenza Resistance Information Study
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4561
- Registration Number
- NCT00884117
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 934
- Registration Number
- NCT00883753
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 451
- Registration Number
- NCT00883779
A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT00882713
A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT00882674
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT00875979
Β© Copyright 2025. All Rights Reserved by MedPath